Format

Send to

Choose Destination
Trends Pharmacol Sci. 2002 Jan;23(1):40-5.

Pharmacological inhibitors of MAPK pathways.

Author information

1
(1) Dept of Biological Research-Oncology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033. (2) Dept of Pharmacology, U.T.Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9041. mcobb@mednet.swmed.edu

Abstract

Mitogen-activated protein kinases [MAPKs, also called extracellular signal-regulated kinases (ERKs)] are constituents of numerous signal transduction pathways, and are activated by protein kinase cascades. Intense efforts are under way to develop and evaluate compounds that target components of MAPK pathways. In this article, the current status of inhibitors of MAPK pathways will be presented with a focus on the properties of small-molecule inhibitors of p38, MEK1 and MEK2 protein kinases. Several of these inhibitors are effective in animal models of disease and have advanced to clinical trials for the treatment of inflammatory diseases and cancer. The clinical utility of specifically targeting a subset of cellular signaling cascades and signaling cascades that regulate pleiotropic cellular processes are being evaluated. The results of these efforts have broad implications for the treatment of many diseases.

PMID:
11804650
DOI:
10.1016/s0165-6147(00)01865-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center